Smoking increases risk of second primary lung cancer (SPLC)
the ONA take:
According to a new study published in the journal Cancer, researchers have found that increased tobacco exposure is linked with a higher risk of developing second primary lung cancers (SPLCs) and current smokers have an elevated risk of mortality compared with former and never-smokers.
For the study, researchers identified 1,484 patients who underwent surgery for non-small cell lung cancer (NSCLC) bettween 1995 and 2008. The researchers then analyzed the rates of SPLC based on smoking status and history and examined overall survival, local control, distant metastases, and postoperative mortality.
Of the 1,484 patients identified, 98 were never-smokers. The researchers found that the incidence of SPLC at 3, 5, and 8 years was 5%, 8%, and 16%, respectively. Of the never-smokers, only 1 developed an SPLC. Analyses showed that smoking history was the only independent risk factor for developing SPLC (HR, 1.08; 95% CI: 1.02-1.16, P = 0.031), which results in an 8% increased risk for developing the disease per 10 pack-year history.
Researchers found similar rates of local control and distant metastases among all smoking smoking statuses. Never-smokers had a decreased postoperative mortality compared with ever-smokers.
Increased tobacco exposure is linked with a higher risk of developing second primary lung cancers.
The objective of the current study was to determine the effect of smoking on the development of second primary lung cancers (SPLCs) and other clinical outcomes after surgery for non–small cell lung cancer (NSCLC). SPLCs are rare in never–smokers.
Increasing tobacco exposure is associated with a higher risk of SPLC in patients with a history of smoking. Current smokers have an increased risk of mortality whereas former and never–smokers have comparable survival.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
- Urine Drug Testing Policy Can Assist Opioid Treatment Decisions
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|